Company Overview and News
TOTAL S.A. (TOT - Free Report) has signed a mutual preferred supplier agreement with China Communications Construction Company (“CCCC”) to expand their working relationship worldwide. At present, TOTAL supplies CCCC with fuels and lubricants, mainly in Africa. Per the new agreement, Total and its affiliates will support CCCC on a very large scale by offering tailored solutions for construction, including financing, civil works, onshore and offshore work, pipeline construction and dredging projects located worldwide.
SPWR DIREN PWOPY CVX 1800 5GD SRGRF SAM
Short interest moves among solar and alternative energy stocks were mixed during the two-week reporting period that ended on June 29. Of the companies we watch, short interest fell on two of three solar stocks and on three of four alternative energy stocks.
SPWR CLNE FCELB 5GD SRGRF PEIX FSLR CSIQ PLUG FCEL
Investors in SunPower Corporation (SPWR - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $11 Put had some of the highest implied volatility of all equity options today.
SPWR 5GD SRGRF
TOTAL S.A. (TOT - Free Report) announced that it has completed the acquisition of 73% of Direct Energie. To this end, TOTAL paid 49.1 cents (42 euros) per share, which represents nearly $1.65 billion (1.4 billion euros). The agreement was entered by the two companies this April. (Read more: TOTAL to Expand Electric & Gas Operation Via Acquisition) Long-Term Goal of TOTAL TOTAL is an integrated energy company and has set a goal to expand its green power generation globally.
SPWR DIREN PWOPY 5GD SRGRF CVRR CSIQ
Investors in SunPower Corporation (SPWR - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $11.00 Put had some of the highest implied volatility of all equity options today.
GOOS ABX SPWR 5GD SRGRF AXTA ABX
The declining cost of solar energy in China and the launch of cheaper batteies in the U.S. are going to make solar stocks soar by 2020 or 2021. Investors should buy solar stocks — including First Solar Inc (NASDAQ:FSLR), Daqo New Energy Corp (NYSE:DQ), SunPower Corporation (NASDAQ:SPWR), and JinkoSolar Holding Co Ltd (NYSE:JKS) — now,while they are very cheap, to take advantage of the coming boom.
NEE.PRI NEE.PRJ JKS DQ SPWR NEE.PRC 5GD NEE.PRQ SRGRF NEE.PRR FSLR NEE
Short interest moves among solar and alternative energy stocks were mixed during the two-week reporting period that ended on June 15. Of the companies we watch, short interest rose on two of three solar stocks and on three of four alternative energy stocks.
SPWR CLNE FCELB 5GD SRGRF PEIX FSLR CSIQ PLUG FCEL
ReneSola Ltd. (SOL - Free Report) reported earnings of a penny, per American Depositary Share (ADS) in the first quarter of 2018, which came in line with the Zacks Consensus Estimate. The company had reported a loss of 2 cents per ADS in the year-ago quarter. Revenues ReneSola’s first-quarter net revenue of $44.8 million surpassed the Zacks Consensus Estimate of $30 million by 49.3%. Moreover, revenues reflected a massive improvement from $0.
SPWR MS.PRE SRGRF 5GD MS.PRF MS.PRG MS.PRA MS.PRI MS.PRK MS SOL FSLR CSIQ
On a definitive agreement with SunPower Corporation (SPWR - Free Report) , Enphase Energy (ENPH - Free Report) has agreed to acquire the former’s microinverter business segment for a total purchase consideration of $25 million in cash along with 7.5 million shares of the company. The acquisition is expected to be closed by the end of third-quarter 2018, subject to fulfillment of product qualification and other various conditions, mentioned in definitive asset purchase agreement.
AEE SPWR WEC 5GD SRGRF ENPH CPK
Enphase Energy, Inc. (NASDAQ: ENPH) saw shares up sharply on Wednesday after the firm announced that it would be acquiring SunPower Corp.’s (NASDAQ: SPWR) microinverter business. The transaction is expected to close at the end of the third quarter of 2018.
SPWR 5GD SRGRF ENPH
The futures are trading slightly higher Monday morning as investors are hoping for another solid week like the one the markets produced last week, when both the NASDAQ and the Russell 2000 hit new all-time highs. With the second quarter starting to wind down, some of the companies that will be reporting in July could start releasing earnings warnings, so it pays to stay alert now.
SGEN PK WFCNP APA SPWR XEC DTE NXPI WFC.PRL 5GD DTJ WFC.PRJ COP WFC.PRT MTCH WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX KOS WFC.PRW WFC.PRV MO FRAC WFC WFC.WS OLN INCY SRGRF OAS DTW DTV FDC EEFT TRI SEMG DTY
President Donald Trump's tariff on imported solar panels has led U.S. renewable energy companies to cancel or freeze investments of more than $2.5 billion in large installation projects, along with thousands of jobs, the developers told Reuters.
SOJA SO GAPWP GPJ SPWR 5GD SRGRF FSLR GPE.PRA GPJA GPEPRA
It’s been a downright terrible week for First Solar, Inc. (NASDAQ:FSLR), with the shares off more than 20%. And various other companies in the sector have also come under pressure like ReneSola Ltd. (ADR)(NYSE:SOL), Hanwha Q Cells Co Ltd -ADR (NASDAQ:HQCL) and SunPower Corporation (NASDAQ:SPWR).
SPWR 5GD SRGRF SOL FSLR HQCL
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET